Navigation Links
Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Date:7/8/2009

SAN DIEGO, July 8, 2009 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today the pricing of its public offering of 12,500,000 shares of its common stock at a public offering price of $4.17 per share. All of the shares are being offered by Arena. The gross proceeds to Arena, before expenses, from the sale of the shares are expected to be approximately $52.1 million. The closing of the offering is expected to take place on July 13, 2009. Piper Jaffray & Co. is acting as the sole underwriter in this offering.

A registration statement relating to these securities has been filed with and declared effective by the Securities and Exchange Commission. A prospectus supplement relating to the offering will be filed with the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. When available, copies of the prospectus supplement relating to this offering may be obtained by contacting Piper Jaffray & Co. by mail at 800 Nicollet Mall, Suite 800, Minneapolis, MN 55402 or by telephone at 800.747.3924.

    Contacts:  Jack Lief
               President and CEO

               Robert E. Hoffman
               VP, Finance and CFO
               Arena Pharmaceuticals, Inc.
               858.453.7200, ext. 222

    www.arenapharm.com


'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals Announces Public Offering of Common Stock
2. Cinergy Health Commentary On President Obamas Call for Cost Control, Competition in Health Insurance Arena
3. Arena Pharmaceuticals to Present at the Piper Jaffray Fourth Annual Europe Conference
4. Arena Pharmaceuticals to Receive $100 Million from Deerfield Management
5. New arenavirus discovered as cause of hemorrhagic fever outbreak in South Africa and Zambia
6. Arena Pharmaceuticals to Present at the 34th Annual Deutsche Bank Health Care Conference
7. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2008 Financial Results and to Host Conference Call and Webcast on Thursday, March 12, 2009
9. Arena Pharmaceuticals Announces Initiation by Merck of Phase 2 Clinical Trial of Niacin Receptor Agonist
10. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
11. Arena Pharmaceuticals to Host Research & Development Day on December 15, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term ... Since first offering the procedure in April of 2015, Florida Hospital Pepin Heart ...
(Date:5/5/2016)... ... ... Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team Semper Fi ... Bike Camp, hosted in conjunction with WTB and Cannondale in Novato, ... share pro tips with the injured veterans as they rip down some of the best ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and Kunshan Gao tested ... seaweeds. The pair observed that when photosynthetically active radiation (i.e. the white light ...
(Date:5/5/2016)... ... May 05, 2016 , ... LELO has discovered ... day, LELO fans reach out via email, social media and on the Volonté blog ... “Is the way I masturbate ‘normal’ or ‘correct’?” , While some methods are more ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... TOWN, Grand Cayman , May 5, 2016 ... successful trial of Oxitec , s ... reduced Aedes aegypti by 96 ... Unit (MRCU) announced a new plan to fight wild Aedes aegypti, ... of these diseases on the island of Grand Cayman . ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
(Date:5/5/2016)... DUBLIN , May 5, 2016 /PRNewswire/ ... the addition of the  "Europe Thalassaemia Market ... to their offering.       (Logo: ... research Europe Thalassaemia Market and Competitive Landscape ... Thalassaemia pipeline products, Thalassaemia epidemiology, Thalassaemia market ...
Breaking Medicine Technology: